Comparative Effectiveness of Levothyroxine, Desiccated Thyroid Extract, and Levothyroxine+Liothyronine in Hypothyroidism

Mohamed K M Shakir, Daniel I Brooks, Elizabeth A McAninch, Tatiana L Fonseca, Vinh Q Mai, Antonio C Bianco, Thanh D Hoang, Mohamed K M Shakir, Daniel I Brooks, Elizabeth A McAninch, Tatiana L Fonseca, Vinh Q Mai, Antonio C Bianco, Thanh D Hoang

Abstract

Introduction: Studies comparing levothyroxine (LT4) therapy with LT4 + liothyronine (LT3) or desiccated thyroid extract (DTE) did not detect consistent superiority of either treatment. Here, we investigated these therapies, focusing on the whole group of LT4-treated hypothyroid patients, while also exploring the most symptomatic patients.

Methodology: Prospective, randomized, double-blind, crossover study of 75 hypothyroid patients randomly allocated to 1 of 3 treatment arms, LT4, LT4 + LT3, and DTE, for 22 weeks. The primary outcomes were posttreatment scores on the 36-point thyroid symptom questionnaire (TSQ-36), 12-point quality of life general health questionnaire (GHQ-12), the Wechsler memory scale-version IV (VMS-IV), and the Beck Depression Inventory (BDI). Secondary endpoints included treatment preference, biochemical and metabolic parameters, etiology of hypothyroidism, and Thr92Ala-DIO2 gene polymorphism. Analyses were performed with a linear mixed model using subject as a random factor and group as a fixed effect.

Results: Serum TSH remained within reference range across all treatment arms. There were no differences for primary and secondary outcomes, except for a minor increase in heart rate caused by DTE. Treatment preference was not different and there were no interferences of the etiology of hypothyroidism or Thr92Ala-DIO2 gene polymorphism in the outcomes. Subgroup analyses of the 1/3 most symptomatic patients on LT4 revealed strong preference for treatment containing T3, which improved performance on TSQ-36, GHQ-12, BDI, and visual memory index (VMS-IV component).

Conclusions: As a group, outcomes were similar among hypothyroid patients taking DTE vs LT4 + T3 vs LT4. However, those patients that were most symptomatic on LT4 preferred and responded positively to therapy with LT4 + LT3 or DTE.

Trial registration: ClinicalTrials.gov NCT02317926.

Keywords: desiccated thyroid extract; hypothyroidism; levothyroxine; liothyronine; quality of life.

© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society.

Figures

Figure 1.
Figure 1.
Flow diagram: enrollment, allocation, and completion of the study. Numbers of patients in each arm indicated in parentheses. DTE, desiccated thyroid extract; LT3- liothyronine; LT4, levothyroxine.
Figure 2.
Figure 2.
Boxplots showing change scores from LT4 to the LT4/LT3 combination treatment, segmented by either low, medium, or high scores for those measures while on LT4. P value reports the results of a pairwise Dunn test for each set of comparisons. Multiple comparisons are adjusted using the Holm method.
Figure 3.
Figure 3.
Boxplots showing change scores from LT4 to the DTE treatment, segmented by either low, medium, or high scores for those measures while on LT4. P value reports the results of a pairwise Dunn test for each set of comparisons. Multiple comparisons are adjusted using the Holm method.
Figure 4.
Figure 4.
A visualization of the pairwise correlation matrix between the various dependent measures, collected during treatment A. Positive correlations are displayed in blue with negative correlations displayed in red; the size of the circle and the intensity of the color denotes correlation strength. The diagonal is marked with a straight line of solid blue circles.
Figure 5.
Figure 5.
Boxplots showing change scores from LT4 to the DTE treatment, segmented by either low, medium, or high scores for those measures while on LT4. P value reports the results of a pairwise Dunn test for each set of comparisons. Multiple comparisons are adjusted using the Holm method.

References

    1. Chaker L, Bianco AC, Jonklaas J, Peeters RP. Hypothyroidism. Lancet. 2017;390(10101):1550-1562.
    1. Aoki Y, Belin RM, Clickner R, Jeffries R, Phillips L, Mahaffey KR. Serum TSH and total T4 in the United States population and their association with participant characteristics: National Health and Nutrition Examination Survey (NHANES 1999-2002). Thyroid. 2007;17(12):1211-1223.
    1. Idrees T, Palmer S, Maciel RMB, Bianco AC. Liothyronine and desiccated thyroid extract in the treatment of hypothyroidism. Thyroid. 2020;30(10):1399-1413.
    1. Taylor S, Kapur M, Adie R. Combined thyroxine and triiodothyronine for thyroid replacement therapy. Br Med J. 1970;2(5704):270-271.
    1. Roberts ND. Psychological problems in thyroid disease. Br Thyroid Foundation Newsl. 1996;18:3.
    1. Saravanan P, Chau WF, Roberts N, Vedhara K, Greenwood R, Dayan CM. Psychological well-being in patients on ‘adequate’ doses of l-thyroxine: results of a large, controlled community-based questionnaire study. Clin Endocrinol (Oxf). 2002;57(5):577-585.
    1. Wekking EM, Appelhof BC, Fliers E, et al. . Cognitive functioning and well-being in euthyroid patients on thyroxine replacement therapy for primary hypothyroidism. Eur J Endocrinol. 2005;153(6):747-753.
    1. Jonklaas J, Bianco AC, Bauer AJ, et al. ; American Thyroid Association Task Force on Thyroid Hormone Replacement . Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid. 2014;24(12):1670-1751.
    1. Jonklaas J, Bianco AC, Cappola AR, et al. . Evidence-based use of levothyroxine/liothyronine combinations in treating hypothyroidism: a consensus document. Thyroid. 2021;31(2):156-182.
    1. Appelhof BC, Fliers E, Wekking EM, et al. . Combined therapy with levothyroxine and liothyronine in two ratios, compared with levothyroxine monotherapy in primary hypothyroidism: a double-blind, randomized, controlled clinical trial. J Clin Endocrinol Metab. 2005;90(5):2666-2674.
    1. Escobar-Morreale HF, Botella-Carretero JI, Gómez-Bueno M, Galán JM, Barrios V, Sancho J. Thyroid hormone replacement therapy in primary hypothyroidism: a randomized trial comparing L-thyroxine plus liothyronine with L-thyroxine alone. Ann Intern Med. 2005;142(6):412-424.
    1. Hoang TD, Olsen CH, Mai VQ, Clyde PW, Shakir MK. Desiccated thyroid extract compared with levothyroxine in the treatment of hypothyroidism: a randomized, double-blind, crossover study. J Clin Endocrinol Metab. 2013;98(5):1982-1990.
    1. Peeters RP, van Toor H, Klootwijk W, et al. . Polymorphisms in thyroid hormone pathway genes are associated with plasma TSH and iodothyronine levels in healthy subjects. J Clin Endocrinol Metab. 2003;88(6):2880-2888.
    1. Mentuccia D, Proietti-Pannunzi L, Tanner K, et al. . Association between a novel variant of the human type 2 deiodinase gene Thr92Ala and insulin resistance: evidence of interaction with the Trp64Arg variant of the beta-3-adrenergic receptor. Diabetes. 2002;51(3):880-883.
    1. Wechsler DA. The Wechsler Memory Scalle-IV. 4th ed. San Antonio, TX: Psychological Corp; 2009.
    1. Benson N, Hulac DM, Kranzler JH. Independent examination of the Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV): what does the WAIS-IV measure? Psychol Assess. 2010;22(1):121-130.
    1. Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial. Jama. 2003;290(22):2952-2958.
    1. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-571.
    1. McDowell I, Newell C.. The General Health Questionnaire, Measuring Health. A guide to Rating Scales and Questionnaires. 2nd ed. New York, NY: Oxford University Press; 1996.
    1. Jaeschke R, Guyatt G, Cook D, Harper S, Gerstein HC. Spectrum of quality of life impairment in hypothyroidism. Qual Life Res. 1994;3(5):323-327.
    1. Cooper DS, Halpern R, Wood LC, Levin AA, Ridgway EC. L-Thyroxine therapy in subclinical hypothyroidism. A double-blind, placebo-controlled trial. Ann Intern Med. 1984;101(1):18-24.
    1. Turner HL, van Etten J, Firth D, Kosmids J. Modelling rankings in R: the PlackettLuce package. Comput Stat. 2020;35:1027-1057.
    1. Peterson SJ, Cappola AR, Castro MR, et al. . An online survey of hypothyroid patients demonstrates prominent dissatisfaction. Thyroid. 2018;28(6):707-721.
    1. Peterson SJ, McAninch EA, Bianco AC. Is a normal TSH synonymous with “euthyroidism” in levothyroxine monotherapy? J Clin Endocrinol Metab. 2016;101(12):4964-4973.
    1. Ettleson MD, Bianco AC. Individualized therapy for hypothyroidism: is T4 enough for everyone? J Clin Endocrinol Metab. 2020;105(9):e3090-e3104.
    1. Valizadeh M, Seyyed-Majidi MR, Hajibeigloo H, Momtazi S, Musavinasab N, Hayatbakhsh MR. Efficacy of combined levothyroxine and liothyronine as compared with levothyroxine monotherapy in primary hypothyroidism: a randomized controlled trial. Endocr Res. 2009;34(3):80-89.
    1. Walsh JP, Shiels L, Lim EM, et al. . Combined thyroxine/liothyronine treatment does not improve well-being, quality of life, or cognitive function compared to thyroxine alone: a randomized controlled trial in patients with primary hypothyroidism. J Clin Endocrinol Metab. 2003;88(10):4543-4550.
    1. Rodriguez T, Lavis VR, Meininger JC, Kapadia AS, Stafford LF. Substitution of liothyronine at a 1:5 ratio for a portion of levothyroxine: effect on fatigue, symptoms of depression, and working memory versus treatment with levothyroxine alone. Endocr Pract. 2005;11(4):223-233.
    1. Sawka AM, Gerstein HC, Marriott MJ, MacQueen GM, Joffe RT. Does a combination regimen of thyroxine (T4) and 3,5,3’-triiodothyronine improve depressive symptoms better than T4 alone in patients with hypothyroidism? Results of a double-blind, randomized, controlled trial. J Clin Endocrinol Metab. 2003;88(10):4551-4555.
    1. Bianco AC, Dumitrescu A, Gereben B, et al. . Paradigms of dynamic control of thyroid hormone signaling. Endocr Rev. 2019;40(4):1000-1047.
    1. López-Espíndola D, García-Aldea Á, Gómez de la Riva I, et al. . Thyroid hormone availability in the human fetal brain: novel entry pathways and role of radial glia. Brain Struct Funct. 2019;224(6):2103-2119.
    1. Morte B, Bernal J. Thyroid hormone action: astrocyte-neuron communication. Front Endocrinol (Lausanne). 2014;5:82.
    1. Marcelino CP, McAninch EA, Fernandes GW, Bocco BMLC, Ribeiro MO, Bianco AC. Temporal pole responds to subtle changes in local thyroid hormone signaling. J Endocr Soc. 2020;4(11):bvaa136.
    1. Freitas BC, Gereben B, Castillo M, et al. . Paracrine signaling by glial cell-derived triiodothyronine activates neuronal gene expression in the rodent brain and human cells. J Clin Invest. 2010;120(6):2206-2217.

Source: PubMed

3
購読する